Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795609 | 0.84 | HTT (0.49) | GCKMAPK14HTTMAPK13MEN1 | |
| SCHEMBL13788542 | 0.83 | HTT (0.56) | GCKMAPK14HTTMAPK13MEN1 | |
| SCHEMBL25746357 | 0.82 | GCK (0.37) | GCKMAPK14BRAF | |
| SCHEMBL24007188 | 0.82 | PIK3C3 (0.48) | GCKMAPK14MAPK13PIK3C3 | |
| SCHEMBL16037109 | 0.80 | MAPK14 (0.46) | GCKMAPK14MAPK13CYP1A2GAA | |
| SCHEMBL25442171 | 0.79 | GCK (0.42) | GCKMAPK14CYP1A2GAAMEN1 | |
| SCHEMBL23795587 | 0.77 | MAPK14 (0.50) | GCKMAPK14MAPK13BRAF | |
| SCHEMBL30313600 | 0.77 | MAPK14 (0.50) | GCKMAPK14MAPK13BRAF | |
| SCHEMBL4321912 | 0.76 | HTT (0.47) | GCKMAPK14HTTMEN1KMT2A | |
| SCHEMBL4326000 | 0.75 | MAPK14 (0.53) | GCKMAPK14MAPK13BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | GCK 2344/4885MAPK14 596/4885HTT 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.